pharmaceuticals

IMPACT FACTOR 4.3

Indexed in: PubMed

CITESCORE 6.1

an Open Access Journal by MDPI

Calcium Channels as Therapeutic Targets

Guest Editors:

Prof. Dr. Gary J. Stephens
School of Pharmacy, University of Reading, Whiteknights, PO Box 228, Reading RG6 6AJ, UK

Prof. Dr. David Adams
Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Wollongong, NSW 2522, Australia

Dr. Hussein N. Rubaiy
Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institute & Karolinska University Hospital, C1:68, 141 86 Stockholm, Sweden

Deadline for manuscript submissions:
31 December 2024

Message from the Guest Editors

Ion channels are key modulators of intracellular levels of Ca^{2+}, which, in turn, is a vital physiological 'second messenger'. Whether modulated through voltage changes, endogenous ligands/protein partners, and/or changes to Ca^{2+} levels, different Ca^{2+} channel families represent key molecular targets in a range of pathophysiologies that carry a heavy health, well-being, and economic burden. Thus, Ca^{2+} channels are major targets in diseases, including pain, epilepsy, neurodegenerative disorders, and neuropsychiatric disorders.

This Special Issue will shed light on new pharmacological agents that modulate different classes of Ca^{2+} channels, including voltage-gated and transient receptor potential channels and/or the auxiliary subunits that make up the protein complex. We welcome submissions from diverse fields of studies, including, but not limited to, the development of small molecular entities and biological drugs, the development of toxins from the plant and animal kingdoms, the exploitation of knowledge of Ca^{2+} channel structure and function, and genetic studies of channelopathies and disease association.

pharmaceuticals

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 6.1

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com